SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of
1934
March 31, 2021
Commission
File Number 001-14978
SMITH & NEPHEW
plc
(Registrant's
name)
Building 5, Croxley Park,
Hatters Lane, Watford, Hertfordshire, WD18 8YE,
England
(Address
of registrant's principal executive offices)
[Indicate
by check mark whether the registrant files or will file
annual
reports
under cover Form 20-F or Form 40-F.]
Form
20-F
X
Form 40-F
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(1).]
Yes
No X
---
---
[Indicate
by check mark if the registrant is submitting the Form 6-K
in
paper
as permitted by Regulation S-T Rule 101(b)(7).]
Yes
No X
---
---
[Indicate
by check mark whether by furnishing the information
contained
in this
Form, the registrant is also thereby furnishing information to
the
Commission
pursuant to Rule 12g3-2 (b) under the Securities Exchange Act
of
1934.]
Yes
No X
---
---
If
"Yes" is marked, indicate below the file number assigned to
the
registrant
in connection with Rule 12g3-2 (b) : 82- n/a.
Smith+Nephew Additional Annual General Meeting update
31 March 2021
Further to the Notice of Annual General Meeting ("2021 Notice of
Meeting") published on 1 March 2021, Smith+Nephew (LSE:SN,
NYSE:SNN), the global medical technology business, confirms the
following in respect of the format of its Annual General
Meeting ("AGM") to be held at 4:00 pm on Wednesday, 14 April
2021.
The Government's updated COVID-19 guidance, issued on 29 March
2021, reiterated that restrictions remain in place across the
country preventing individuals from different households mixing
indoors and requesting that people 'minimise travel'. Shareholders
are therefore reminded they must not physically attend the AGM, in line with the
Government's measures and restrictions that will be in force at the
date of the AGM.
The AGM will be conducted as a hybrid meeting, enabling
shareholders to attend and participate (voting and raising
questions) by electronic means. A free phone telephone facility is
also available to shareholders who may not have access to a
Computer and wish to listen to the meeting and raise questions by
telephone. Further information on how shareholders can join the
hybrid meeting electronically via an online meeting platform,
submit questions and vote can be found on pages 17-19 of our 2021
Notice of Meeting. Please be reminded that shareholders will
require their SRN and PIN to access the meeting electronically.
These can be found printed on your Form of Proxy or in your email
notification, if you have chosen to receive shareholder
communications electronically. The physical meeting will only be
attended by the Chair, Chief Financial Officer and the Company
Secretary, with all other Directors attending
electronically.
The hybrid AGM will commence at 4:00 pm on Wednesday, 14 April 2021
but shareholders should note that electronic entry to the meeting
via the online meeting platform will open at 3:30 pm.
Enquiries
Investors/ Analysts
Andrew Swift
+44 (0) 1923 477433
Smith+Nephew
Media
Charles Reynolds
+44 (0) 1923 477314
Smith+Nephew
About Smith+Nephew
Smith+Nephew is a portfolio medical technology business that exists
to restore people's bodies and their self-belief by using
technology to take the limits off living. We call this purpose
'Life Unlimited'. Our 18,000 employees deliver this mission every
day, making a difference to patients' lives through the
excellence of our product portfolio, and the invention and
application of new technologies across our three global
franchises of Orthopaedics, Advanced Wound Management and Sports
Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in
more than 100 countries, and generated annual sales of $4.6 billion
in 2020. Smith+Nephew is a constituent of the FTSE100 (LSE:SN,
NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer
to Smith & Nephew plc and its consolidated subsidiaries,
unless the context requires otherwise.
For more information about Smith+Nephew, please
visit www.smith-nephew.com and
follow us on Twitter, LinkedIn, Instagram or Facebook.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith+Nephew, these factors include: risks
related to the impact of COVID-19, such as the depth and longevity
of its impact, government actions and other restrictive measures
taken in response, material delays and cancellations of elective
procedures, reduced procedure capacity at medical facilities,
restricted access for sales representatives to medical facilities,
or our ability to execute business continuity plans as a result of
COVID-19; economic and financial conditions in the markets we
serve, especially those affecting health care providers, payers and
customers (including, without limitation, as a result of COVID-19);
price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers
(including, without limitation, as a result of COVID-19);
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that
Smith+Nephew has filed with the U.S. Securities and Exchange
Commission under the U.S. Securities Exchange Act of 1934, as
amended, including Smith+Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith+Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith+Nephew are
qualified by this caution. Smith+Nephew does not undertake any
obligation to update or revise any forward-looking statement to
reflect any change in circumstances or in Smith+Nephew's
expectations.
◊ Trademark
of Smith+Nephew. Certain marks registered US Patent and Trademark
Office.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
Smith
& Nephew Plc
(Registrant)
Date: March
31, 2021
By: /s/
Susan Swabey
-----------------
Susan
Swabey
Company
Secretary
Smith and Nephew (PK) (USOTC:SNNUF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Smith and Nephew (PK) (USOTC:SNNUF)
Historical Stock Chart
From Jul 2023 to Jul 2024